Novavax (NVAX) Net Income towards Common Stockholders (2010 - 2026)

Novavax's Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$9.5 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 101.83% year-over-year to -$9.5 million in Q1 2026; TTM through Mar 2026 was -$87.8 million, a 118.35% decrease from a year earlier, with the FY2025 full-year figure at $440.3 million, up 334.83% from the prior year.
• Net Income towards Common Stockholders slipped to -$9.5 million in Q1 2026 per NVAX's latest filing, from $17.5 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $518.6 million in Q1 2025 and bottomed at -$510.5 million in Q2 2022.
• The 5-year median for Net Income towards Common Stockholders is -$121.3 million (2024), against an average of -$56.5 million.
• Across the five-year window, Net Income towards Common Stockholders slumped 244.49% in 2023 and surged 451.51% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$182.2 million in 2022, then rose by 2.12% to -$178.4 million in 2023, then jumped by 54.58% to -$81.0 million in 2024, then jumped by 121.63% to $17.5 million in 2025, then slumped by 154.15% to -$9.5 million in 2026.
• Per Business Quant, the three latest NVAX Net Income towards Common Stockholders figures stand at -$9.5 million (Q1 2026), $17.5 million (Q4 2025), and -$202.4 million (Q3 2025).